We started a phase II / III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer’s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein

Compartir:
CategoryAlzeimer

No dude en llamarnos        1-+34 935 656 000